Navigation Links
Stem Cell Finding Could Expand Women's Lifetime Supply of Eggs
Date:2/27/2012

By Jenifer Goodwin
HealthDay Reporter

SUNDAY, Feb. 26 (HealthDay News) -- Researchers report that they've isolated stem cells from adult human ovaries that can mature into eggs that may be capable of fertilization.

The lab findings, which upend longstanding scientific theory, could potentially lead to new reproductive technologies and possibly extend the years of a woman's fertility.

It was long believed that women were born with a lifetime supply of eggs, which was depleted by menopause. But a growing body of research -- including a new paper from Massachusetts General Hospital -- suggests egg production may continue into adulthood. The study is published in the March issue of Nature Medicine.

"Fifty years of thinking, in every aspect of experiments, of interpreting the results, and of the clinical management of ovarian function and fertility in women was dictated by one simple belief that turns out to be incorrect," said lead study author Jonathan Tilly, director of the hospital's Vincent Center for Reproductive Biology. "That belief was the egg cell pool endowed at birth is a fixed entity that cannot be renewed."

Dr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore-LIJ Health System in Manhasset, N.Y., said the study is "exciting" but emphasized the work is still very preliminary.

"This is experimental," Hershlag said. "This is a beginning of perhaps something that could bring in new opportunities, but it's going to be a long time in my estimation until clinically we'll be able to actually have human eggs created from stem cells that make babies."

The same team at Mass General caused a stir in 2004 when it published a paper in Nature reporting that female mice retain the ability to make new egg cells well into adulthood.

In both mice and humans, the vast majority of egg cells die through a process called programmed cell death, or apoptos
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
2. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
3. VARI findings may help patients with deadly kidney cancer
4. UMass Lowell researchers findings suggest new ways to diagnose and treat Alzheimers
5. MatchMySport.com Aims to Reduce Obesity Levels Through Sports Participation by Finding Sports Partners/Players/Teams
6. Research findings expected to ease treatment of low neutrophil counts in cancer patients
7. Cedars-Sinai Heart Institute physicians present findings at ACC scientific meeting
8. Cosmetic and Plastic Surgery Web Site Announces Improvements to the Patient Process of Finding Cosmetic Doctors in Their Area
9. ACS Webinar features tips for finding and building a career in public policy and chemical industry
10. Finding Good Migraine Care a Headache for the Uninsured
11. Research findings underscore needed action to safeguard lungs of young cancer survivors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stem Cell Finding Could Expand Women's Lifetime Supply of Eggs
(Date:7/24/2014)... Texas at Arlington professor who co-authored a book ... in community revitalization has been awarded the Community ... Martinez-Cosio, associate professor in the School of Urban ... week at the society,s national conference, along with ... academic coordinator in the Urban Studies and Planning ...
(Date:7/24/2014)... sufficient to read the declaration of contents if you need ... to do this you need to be a highly skilled ... can look directly into the molecular structure of the various ... is almost both, as he has developed a method that ... samples. , The ,Fingerprints, of a Substance , ...
(Date:7/24/2014)... growing number of U.S. teens are using synthetic human ... ability, a new study finds. The percentage ... 11 percent in 2013 -- more than double the ... the Partnership for Drug-Free Kids revealed. The ... oversight of performance-enhancing substances and other "fitness" products, the ...
(Date:7/24/2014)... Recently, Stwd.co.uk, a professional supplier of wedding dresses and special ... new designs of cheap wedding dresses to its ... with big discounts. According to the CEO of the company, ... fashionable items. They are available at low rates, up to ... dress was previously priced at $150, and it is offered ...
(Date:7/24/2014)... 2014 Hayes, Inc. ( http://www.hayesinc.com ), ... use of evidence, is pleased to announce that Dee ... guest speaker at the AHRMM14 Conference in ... expert in value analysis who also serves as the ... Professionals (AHVAP), will facilitate and participate in two preconference ...
Breaking Medicine News(10 mins):Health News:Strategy for community development partnerships earns award for UT Arlington professor 2Health News:Chemist develops X-ray vision for quality assurance 2Health News:Chemist develops X-ray vision for quality assurance 3Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 2Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 3Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 4Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 5Health News:Cheap Wedding Dresses Are Offered by Stwd.co.uk at Low Prices 2Health News:Hayes, Inc. Senior Vice President to Speak at AHRMM14 Conference 2Health News:Hayes, Inc. Senior Vice President to Speak at AHRMM14 Conference 3
... Dr. Jane Carlton of the New York University School of ... , The one-celled bacterium is the causal organism ... transmitted and more severe among women. The infection is spread ... etc. ,In addition to causing uncomfortable itching in the ...
... normal life was affected by a parrot was rendered an amount ... used to work for a pet shop had fallen sick and ... like ordinary fever. But subsequent diagnosis revealed that he was suffering ... have direct contact with the sick African Grey but he is ...
... high levels of dangerous cholesterol in their blood.// ... of an experimental drug, AEGR-733, in six patients with ... to store bad cholesterol. The drug proved extremely beneficial ... be the most promising in the heap of prevalent ...
... implanted human emotions to a train was helpful to autistic ... conducted by Professor Simon Baron Cohen who is the director ... conducted among children in the age group of 4-8. ... there was a marked improvement in these children in recognizing ...
... witnessed a surge in the number of obesity surgeries, US statistics ... have gone up by 2000 percent amongst the 55 to 64 ... of 18 to 24. The procedures which are clubbed under the ... obese or who suffer chronic illnesses due to obesity. ...
... hundred villages in India will soon be well equipped ... centers - with the active involvement// of Indian American ... we would promote better hygiene, clean drinking water and ... also be given to creating awareness about vector borne ...
Cached Medicine News:Health News:Hypercholesterolemia Meets Its Match in an Experimental Drug 2Health News:Better Healthcare for 100 Villages - Courtesy Indian American Physicians 2
(Date:7/24/2014)... July 24, 2014 Celsion Corporation (NASDAQ: ... data from its ongoing open-label Phase 2 DIGNITY ... Cancer (RCWBC).  The trial is designed to enroll ... is evaluating ThermoDox in combination with mild hyperthermia. ... eligible for evaluation of efficacy.  Based on data ...
(Date:7/24/2014)... HIGHLIGHTS:Q2 2014 Results (all percentage changes ... sales increased 3% to $701 million.  Sales grew organically by ... percentage point to sales growth. , By business unit, ... and 1% in SAFC Commercial. , Reported diluted EPS ... of 13%.  Adjusted diluted EPS in Q2 2014 was also ...
(Date:7/24/2014)... and VANCOUVER, British Columbia , ... OGXI ) announced today that the Company,s ... Thursday, August 7, 2014, and that the Company will ... p.m. ET that afternoon. Management will provide an overview ... general business update. To access the ...
Breaking Medicine Technology:Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer 2Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 16Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 17Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 18Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 19Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 20Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 21Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 22OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014 2
... 26 Bristol-Myers Squibb,Company (NYSE: BMY ) ... in which treatment of antiviral-naive adult chronic hepatitis ... viral,load reduction than adefovir at 96 weeks -- ... viral load to undetectable,levels is a measure of ...
... ... C Clarification of Oncogenic Pathways Aids ... Benefit in Liver Transplantation, MILAN, April 26 , - Systems Biology Helps ... of the European,Association for the Study of the Liver (EASL), experts reported advances in,basic ...
Cached Medicine Technology:BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 2BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 3BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 4BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 5BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 6BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 7Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Medicine Products: